2185 — Shanghai Bio-heart Biological Technology Share Price
Last trade - 00:00- HK$287.23m
- HK$427.15m
- CNY44.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.61 | ||
| Price to Tang. Book | 1.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.05% | ||
| Return on Equity | -17.16% | ||
| Operating Margin | -242.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | n/a | 44.93 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shanghai Bio-heart Biological Technology Co Ltd is a China-based company primarily engaged in the research and development or commercialization of interventional cardiovascular device. The Company’s products primarily include the Bioheart bioresorbable scaffold (BRS) system for percutaneous coronary intervention procedures, Iberis second-generation renal denervation (RDN) system for the treatment of hypertension, and drug coated balloon (DCB) for the treatment of in-stent restenosis. The Company primarily operates its business in the domestic market.
Directors
- Wang Li CHM (52)
- Yunqing Wang CFO (37)
- Tao Cai OTH (35)
- Bradley Hubbard OTH (63)
- Peili Wang OTH (38)
- Chenzhao Zhang OTH (38)
- Siu Ying Kwok SEC (37)
- Li Cai NED (38)
- Ji Chen NED (34)
- Jie Yin NED (46)
- Quan Zhou NED (45)
- Sheung Wai Chan NID (67)
- Chien Cheng Lin NID (51)
- Xubo Lu NID (41)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 18th, 2014
- Public Since
- December 23rd, 2021
- No. of Employees
- 63
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 243,417,100
- Address
- Room 302, 3/F, Building 4, SHANGHAI, 2012201
- Web
- http://www.bio-heart.com/
- Phone
- +86 2168798511
- Auditors
- Ernst & Young CPA
Latest News for 2185
Upcoming Events for 2185
Similar to 2185
Acotec Scientific Holdings
Stock Exchange of Hong Kong Limited
Beijing Airdoc Technology
Stock Exchange of Hong Kong Limited
AK Medical Holdings
Stock Exchange of Hong Kong Limited
AMCO United Holding
Stock Exchange of Hong Kong Limited
Angelalign Technology
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 01:37 UTC, shares in Shanghai Bio-heart Biological Technology are trading at HK$1.18. This share price information is delayed by 15 minutes.
Shares in Shanghai Bio-heart Biological Technology last closed at HK$1.18 and the price had moved by -86.96% over the past 365 days. In terms of relative price strength the Shanghai Bio-heart Biological Technology share price has underperformed the FTSE Developed Asia Pacific Index by -90.48% over the past year.
There is no consensus recommendation for this security.
Find out moreShanghai Bio-heart Biological Technology does not currently pay a dividend.
Shanghai Bio-heart Biological Technology does not currently pay a dividend.
Shanghai Bio-heart Biological Technology does not currently pay a dividend.
To buy shares in Shanghai Bio-heart Biological Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$1.18, shares in Shanghai Bio-heart Biological Technology had a market capitalisation of HK$287.23m.
Here are the trading details for Shanghai Bio-heart Biological Technology:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2185
Based on an overall assessment of its quality, value and momentum Shanghai Bio-heart Biological Technology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shanghai Bio-heart Biological Technology. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -74.68%.
As of the last closing price of HK$1.18, shares in Shanghai Bio-heart Biological Technology were trading -66.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shanghai Bio-heart Biological Technology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shanghai Bio-heart Biological Technology's management team is headed by:
- Wang Li - CHM
- Yunqing Wang - CFO
- Tao Cai - OTH
- Bradley Hubbard - OTH
- Peili Wang - OTH
- Chenzhao Zhang - OTH
- Siu Ying Kwok - SEC
- Li Cai - NED
- Ji Chen - NED
- Jie Yin - NED
- Quan Zhou - NED
- Sheung Wai Chan - NID
- Chien Cheng Lin - NID
- Xubo Lu - NID